[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554367":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":69,"collaborators":71,"id":85,"slug":10,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":10,"enrollmentInfo":93,"targetDuration":10,"studyType":96,"phases":10,"briefSummary":97,"conditions":98,"keywords":105,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Universidade do Porto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Upadatacinib Arm",null,"Patients exposed to upadacitinib (Rinvoq™)",[13],"Drug: Upadacitinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Upadacitinib","Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).",[9],[21,22],"Rinvoq","ATC 200000041628",[24],{"name":25,"affiliation":5,"role":26},"Inês Ribeiro Vaz, PharmD, MPH, PhD","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+ 351220426952","inesvaz@med.up.pt",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":35},"Renato Ferreira da Silva, PharmD","+351220426913","rsilva@med.up.pt",[37,50,63],{"facility":38,"status":39,"city":40,"state":10,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"Unidade Local de Saúde de Santo António, E.P.E.","ACTIVE_NOT_RECRUITING","Porto","4050-366","Portugal","PT",{"type":45,"coordinates":46},"Point",[47,48],-8.61097,41.1485,{"lat":48,"lon":47},{"facility":51,"status":52,"city":40,"state":10,"zip":53,"country":42,"countryCode":43,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"Unidade Local de Saúde de São João, E.P.E.","RECRUITING","4200-319",{"type":45,"coordinates":55},[47,48],{"lat":48,"lon":47},[58,62],{"name":59,"role":29,"phone":60,"phoneExt":10,"email":61},"Manuela Pinto, PharmD","+351225512143","manuela.milne@ulssjoao.min-saud.pt",{"name":59,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":64,"status":39,"city":40,"state":10,"zip":65,"country":42,"countryCode":43,"cosmosGeoPoint":66,"geoPoint":68,"contacts":10},"Unidade Local de Saúde de Gaia\u002FEspinho, E.P.E.","4434-502",{"type":45,"coordinates":67},[47,48],{"lat":48,"lon":47},{"type":70,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[72,75,77,80,81,83],{"name":73,"class":74},"INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.","UNKNOWN",{"name":76,"class":74},"Unidade de Farmacovigilância do Porto",{"name":78,"class":79},"Unidade Local de Saúde São João","OTHER_GOV",{"name":38,"class":74},{"name":82,"class":6},"Unidade Local de Saude de Gaia e Espinho EPE",{"name":84,"class":74},"RISE Health","100554367",false,"NCT06498167","Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)","LOOK-UP","Inclusion Criteria:\n\n* Prescription of Rinvoq™ from January 1, 2024;\n* 18 years of age or older at the time of recruitment; and\n* Expressed consent to participate in the study.\n\nExclusion Criteria:\n\n* They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;\n* They are participating in a phase I, II, or III clinical trial;\n* They have a life expectancy of less than 1 month; or\n* They do not have a valid telephone contact.","ALL","18 Years",{"count":94,"type":95},150,"ESTIMATED","OBSERVATIONAL","The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \\& Co. KG.",[99,100,101,102,103,104],"Inflammatory Disease","Drug Side Effect","Drug Use","Adverse Drug Event","Adverse Drug Reaction","Safety Issues",[17,21,106,107,108,109,110,111,112,113,114],"Rheumatoid arthritis","Psoriatic arthritis","Axial spondyloarthritis","Atopic dermatitis","Ulcerative colitis","Crohn's disease","Pharmacovigilance risk","Drug safety monitoring","Patient Safety","2024-07-12",{"date":117,"type":118},"2024-07-15","ACTUAL",{"date":120,"type":118},"2024-07-01",{"date":122,"type":95},"2024-12-31",{"name":5,"class":6},3]